Jubilant Pharmova (JUBLPHARMA) | Stock Overview & Key Data
Jubilant Pharmova Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,309.90 on November 4, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
JUBLPHARMA
|
149.73B Mid-cap | -1.03% | 4.69% | 14.66% | -11.23% | -7.85% | -15.23% | 196.97% | 18.95% | 275.66% | 727.37% | 529.39% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | -2.77% | -1.84% | 2.13% | -0.53% | 4.00% | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | -3.26% | -1.31% | 2.02% | 1.80% | 2.98% | 0.83% | 89.86% | 56.44% | 484.44% | 1,625.50% | 9,907.51% |
|
Piramal Pharma
PPLPHARMA
|
199.68B Mid-cap | -6.68% | 4.13% | 9.23% | -9.90% | -1.74% | -16.24% | 115.91% | 3.17% | 3.17% | 3.17% | 3.17% |
|
Eris Lifesciences
ERIS
|
193.36B Mid-cap | 0.05% | 0.63% | 0.12% | -13.23% | -9.28% | -11.56% | 119.21% | 94.70% | 132.59% | 132.59% | 132.59% |
|
Neuland Laboratories
NEULANDLAB
|
184.81B Mid-cap | -0.95% | 4.87% | 29.12% | 3.39% | 12.28% | 48.55% | 510.11% | 716.28% | 2,058.53% | 16,354.50% | 19,900.00% |
Ownership & Short Interest
Calculate Your Jubilant Pharmova Investment Returns
Long-Term Investment Performance Analysis
Jubilant Pharmova stock price in May 2016 was ₹264.87, A ₹1,000.00 lump sum investment in Jubilant Pharmova made 10 years ago would be worth approximately ₹3,695.59 today, representing a outstanding return of 269.56%. This translates to an annualized return (CAGR) of 13.95%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is JUBLPHARMA's 52-week high and low?
- In the last 52 weeks, Jubilant Pharmova reached a high of ₹1,248.00 (on July 30, 2025) and a low of ₹786.05 (on March 9, 2026).
- What is the market cap and P/E ratio for JUBLPHARMA?
- Curious about Jubilant Pharmova's size and valuation? Its market capitalization stands at 149.73B. When it comes to valuation, the P/E ratio (trailing twelve months) is 33.71, and the forward P/E (looking ahead) is 25.27.
- Does JUBLPHARMA pay dividends? If so, what's the yield?
- Yes, Jubilant Pharmova is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.85%, and the company has paid an average of ₹6.67 per share annually over the past 3 years.
- Who are Jubilant Pharmova's main competitors or similar companies to consider before investing?
When looking at Jubilant Pharmova, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.25% 79.99% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic 0.83% 89.86% Piramal Pharma
PPLPHARMA199.68B Healthcare Drug Manufacturers - Specialty & Generic -16.24% 115.91% Eris Lifesciences
ERIS193.36B Healthcare Drug Manufacturers - Specialty & Generic -11.56% 119.21% Neuland Laboratories
NEULANDLAB184.81B Healthcare Drug Manufacturers - Specialty & Generic 48.55% 510.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Jubilant Pharmova Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Jubilant Pharmova's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.45%, the Debt to Equity ratio from the most recent quarter is 43.87, and its Gross Profit Margin stands at 66.15%.
- What is the recent revenue and earnings growth for JUBLPHARMA?
- Looking at Jubilant Pharmova's growth, its revenue over the trailing twelve months (TTM) was INR79B. Compared to the same quarter last year (YoY), quarterly revenue grew by 16.50%, and quarterly earnings saw a YoY growth of -44.60%.
- How much of JUBLPHARMA stock is held by insiders and institutions?
- Wondering who owns Jubilant Pharmova stock? Company insiders (like executives and directors) hold about 57.94% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 20.51%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.